From Self-sufficiency
Jump to: navigation, search
File:Mubritinib structure.png
Systematic (IUPAC) name
Clinical data
Routes of
Legal status
Legal status
  • Uncontrolled
CAS Number 366017-09-6
ATC code none
PubChem CID 6444692
ChemSpider 4948554
Chemical data
Formula C25H23F3N4O2
Molar mass 468.47 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Mubritinib (TAK-165) is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer.[1][2][3] It completed phase I clinical trials but appears to have been discontinued, as no new information on the drug has surfaced since December 2008.[4]



See also


Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

  1. McCormick, Frank; Doriano Fabbro (2005). Protein Tyrosine Kinases: From Inhibitors to Useful Drugs (Cancer Drug Discovery and Development). Totowa, NJ: Humana Press. ISBN 1-58829-384-X. 
  2. Mitscher, Lester A.; Lednicer, Daniel (1977). The organic chemistry of drug synthesis. New York: Wiley. ISBN 0-470-10750-2. 
  3. Lednicer, Daniel (2008). Strategies for Organic Drug Synthesis and Design. New York: Wiley-Interscience. ISBN 0-470-19039-6. 
  4. "Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 - Full Text View -".